NCT06840080View on ClinicalTrials.gov

OEA and LipiSperse Metabolic Study

PHASE4RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 4, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Healthy Volunteers - Male and FemalePharmacokinetic Study in Healthy Volunteers
Interventions
OTHER

Placebo

Single dose of 2 capsules. Capsules contain the same excipients as the active arms, except for the OEA with LipiSperse in capsules that appear identical to the OEA with LipiSperse capsules

DIETARY_SUPPLEMENT

125mg OEA with LipiSperse

Single dose of 2 capsules. 1 capsule contains 125mg of OEA and 13.9mg of LipiSperse, the other capsule is a placebo.

DIETARY_SUPPLEMENT

250mg OEA with LipiSperse

Single dose of 2 capsules. Each capsule contains 125mg of OEA and 13.9mg of LipiSperse.

Trial Locations (1)

4006

RECRUITING

RDC Clinical, Brisbane

All Listed Sponsors
collaborator

Gencor Pacific Limited

UNKNOWN

lead

RDC Clinical Pty Ltd

INDUSTRY